RAMtherapeutics is at the forefront of a transformative breakthrough in cancer care with our specialized therapy, Triamdocaine MUM™. This innovative powder formulation is designed to prevent and treat severe oral mucositis—a debilitating side effect of radiation therapy for head and neck cancer patients.

Why Invest in Triamdocaine MUM?

• Addressing a Critical Need: Severe oral mucositis impacts a significant portion of cancer patients undergoing radiation therapy, leading to severe pain, reduced quality of life, and increased treatment costs. Triamdocaine MUM offers a targeted solution to this pressing issue.
• Proven Efficacy: RAM Pharmaceuticals, our sister company currently sells a 503B compounded product called Acyclonine MUM in the dental space for use with Oral lesions to include SOM which gives the drug proven track record of efficacy..
• Strong Market Potential: With a growing patient population and increasing demand for effective treatments, there is a substantial market opportunity for Triamdocaine MUM. Our product is poised to meet this need with a differentiated approach.
• Strategic Positioning: By investing in RAMtherapeutics, you will be part of a forward-thinking organization committed to innovation in healthcare. Our team is dedicated to driving the commercialization of Triamdocaine MUM and maximizing its impact on patient care.

Join Us in Making a Difference

We invite you to be a part of this exciting journey. Your investment will enable us to advance the development and commercialization of Triamdocaine MUM, ultimately bringing relief to countless patients and revolutionizing the standard of care for those suffering from severe oral mucositis.

Contact Us to learn more about this investment opportunities and how you can contribute to transforming cancer care with RAMtherapeutics.